UK pharmaceutical giant GSK plc (LON: GSK, NYSE: GSK) has unveiled a significant five-year partnership with the University of Cambridge and Cambridge University Hospitals, backed by a financial commitment of £50 million. This collaboration aims to enhance research and development efforts targeting immune-related diseases.
Dubbed the Cambridge-GSK Translational Immunology Collaboration (CG-TIC), the initiative will concentrate on advancing treatments within the respiratory and renal sectors. By leveraging the complementary strengths of GSK and the University of Cambridge, this partnership will adopt a “translational” approach, integrating artificial intelligence and machine learning while placing patients at the forefront of its research efforts.- Flcube.com
